Almac?s New Clinical Supply Forecasting Tool ? COMPASS ? To Improve Clinical bi2281384 CRAIGAVON, Northern Ireland--(BUSINESSWIRE)-- Almac announces the launch of revolutionary new forecasting platform, COMPASS , has been specifically designed to improve the accuracy and efficiency ..

Marken Launches Solo? For Management Of Clinical Trials Distribution bi2281384 Marken announced recently the launch of Solo?, proprietary web based system used to manage the unique regulatory, inventory and operational supply chain complexities of clinical trials

Clinical Hold Removed for Helix BioPharma Corp.'s Topical Interferon Alpha-2b bi2281384 AURORA, ON-- - Helix BioPharma Corp. , a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that the "clinical hold" on investigational ..

Abbott initiates clinical trial to evaluate Absorb BVS bi2281384 Abbott announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb? bioresorbable vascular scaffold ..

First genome sequencing clinical trial for triple negative cancer points to n bi2281384 ( The Translational Genomics Research Institute ) Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported today during the CRTC-AACR San Antonio Breast Cancer Symposium

PolyMedix Announces Encouraging Interim Results From Multinational Phase 2 Cl bi2281384 Efficacy and Safety Demonstrated All Evaluated Dose Groups..

Genta Announces Results From Clinical Trial of Tesetaxel as Initial Chemother bi2281384 BERKELEY HEIGHTS, N.J. -- Genta Incorporated (OTCBB:GNTA.OB) today announced presentation of results from the Company's Phase 2b clinical trial using tesetaxel as initial, single-agent chemotherapy ..

Abbott Initiates Clinical Trial to Evaluate the Absorb? Bioresorbable Vascula bi2281384 ABBOTT PARK, Ill., Dec. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb? bioresorbable vascular scaffold (BVS)..

Amp Orthopedics Initiates Clinical Trial Knee Osteoarthritis Pain bi2281384 SEATTLE--(BUSINESS WIRE)--Amp Orthopedics, a privately held medical device company, announced the initiation of a clinical trial adults mild-to-moderate knee osteoarthritis (OA) to determine the safety and effectiveness of the company?s non-thermal pulsed radio frequency (PRF) technology to ameliorate pain. The OARS trial a randomized, sham-controlled, double-blind study of 150 ..

Pacific Therapeutics Ltd. Announces Engagement of CRBIO to Conduct Clinical T bi2281384 VANCOUVER, BRITISH COLUMBIA-- - Pacific Therapeutics Ltd. a development stage specialty pharmaceutical company focused on the identification and development of drug candidates to treat diseases of excessive ..

XenoPort Announces XP21279 Phase 2 Clinical Trial Results Patients With Ad bi2281384 SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today preliminary top-line results of a Phase 2, randomized, crossover clinical trial that compared optimized treatment either Sinemet (immediate-release levodopa/carbidopa) or XP21279 co-formulated carbidopa (279/CD) advanced Parkinson?s disease patients motor fluctuations. 279/CD dosed three times ..

Oncolytics Biotech® Inc. Announces Phase 2 Clinical Trial of REOLYSIN® Com bi2281384 Oncolytics Biotech® Inc. Announces Phase 2 Clinical Trial of REOLYSIN® Combination Gemcitabine Pancreatic Cancer Reaches Primary Endpoint..

Press Release bi2281384 Almac announces the launch of revolutionary new forecasting platform, COMPASS, has been specifically designed to improve the accuracy and efficiency of the supply inventory process during clinical studies

Lightning Surge Protection - Home